Immunome (IMNM)
(Delayed Data from NSDQ)
$9.39 USD
-0.46 (-4.67%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.39 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Immunome, Inc. - Hold
Zacks' proprietary data indicates that Immunome, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the IMNM shares relative to the market in the next few months. In addition, Immunome, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Immunome, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of IMNM, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Style Scorecard
Zacks News for IMNM
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services